iwCLL 2023 | Effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in CLL
In this interview, Kerry Rogers, MD, The Ohio State University, Columbus, OH, outlines a study looking into the effects of dose adjustment of first-line ibrutinib in patients with chronic lymphocytic leukemia (CLL) on real-world dosing patterns and outcomes. This study supports the idea that dose reduction – if necessary to manage adverse events – will not decrease efficacy of treatment, as time to next treatment (used as a surrogate for progression free survival) did not differ between those patients who had a dose-reduction and those who did not. In patients with dose-reduction, increased adherence to the treatment was observed. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
